Pays to read the financial analysis which determines the valuation and then read the ASX announcements - you need to read the whole reports, not just the valuations.
The 8.2c valuation factored in a large amount of sales this year with the burette - as the report states, they ran into 6 months of delays when retooling and incorporating the autostart burette and autoflush features into one unit to market it as the Autostart Infusion System rather than 2 separate products - I believe they also patented the new system.
As a result, they have been more conservative on the valuation this time round, however from an F/A perspective, the company has never been more attractive.
End of day, whether the valuation is 5c , 8c or 10c - it is unlikely to trade there based on the report alone. All they are highlighting is it is undervalued - these are just nominal figures based on DCF's
The change in valuation shouldn't detract from the actual content, especially the new product launch into the MHealth market which is nothing short of huge
ALT Price at posting:
2.3¢ Sentiment: Buy Disclosure: Held
